QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

Monday, January 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

SALUGGIA, Italy, HILDEN, Germany, and GERMANTOWN, Maryland, January

8, 2018 /PRNewswire/ --

  • QIAGEN's QuantiFERON-TB customers to gain access to fully automated workflow
    solution  
  • DiaSorin to add novel content to already broad LIAISON menu, over 7,000 systems installed  
  • QIAGEN announces milestone of over 40 million QuantiFERON-TB tests since launch  

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) announced today a groundbreaking partnership that plans to add QIAGEN's QuantiFERON-TB diagnostic test to the menu of DiaSorin's LIAISON family of fully automated analyzers.

This addition will enable customers of both companies to process QuantiFERON-TB Gold Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on LIAISON family platforms. Laboratories using QFT-Plus to safeguard at-risk patients by screening for latent TB infection will have access to a fully automated, flexible workflow on LIAISON family analyzers in addition to the currently available workflow solutions. More than 7,000 LIAISON systems have already placed worldwide, primarily in hospital laboratories.

QFT-Plus marks the first assay from QIAGEN's QuantiFERON portfolio that is planned to be adapted for use on the LIAISON family systems. Additional assays based on QuantiFERON technology, which offers a unique, efficient way to detect asymptomatic infections and other risks that cannot be discovered with standard diagnostic technologies, are under consideration.

QuantiFERON assays such as QFT-Plus are based on two components: (1) QuantiFERON Blood Collection Tubes, which contain key components of the test reaction that is uniquely performed in tube after blood collection; and (2) the QuantiFERON test read-out components, which are used to measure the release of interferon gamma after in-tube incubation. QFT-Plus currently runs in laboratories on standard detection equipment.

Click here for the full press release: https://corporate.qiagen.com/newsroom/press-releases/2017/20180108_DiaSorin_LIAISON_QFT?sc_lang=en

For additional information, please contact For DiaSorin Riccardo Fava Investor Relations & Corporate Communication Senior Director Tel: +39.0161.487988 riccardo.fava@diasorin.it Ines Di Terlizzi Investor Relator Tel: +39.0161.487567     ines.diterlizzi@diasorin.it For QIAGEN Investor Relations John Gilardi Tel: +49 2103 29 11711 e-mail: ir@QIAGEN.com   Public Relations Thomas Theuringer Tel: +49 2103 29 11826 e.mail: pr@QIAGEN.com

SOURCE Qiagen N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store